Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C
Neal D Freedman, Teresa M Curto, Karen L Lindsay, Elizabeth C Wright, Rashmi Sinha, James E Everhart, HALT-C TRIAL GROUP, Maureen Cormier, Donna Giansiracusa, Herbert L Bonkovsky, Gloria Borders, Michelle Kelley, Adrian M Di Bisceglie, Bruce Bacon, Brent Neuschwander-Tetri, Elizabeth M Brunt, Debra King, Harvard Clinical, Jules L Dienstag, Raymond T Chung, Andrea E Reid, Atul K Bhan, Wallis A Molchen, David P Lundmark, Gregory T Everson, Thomas Trouillot, Marcelo Kugelmas, S Russell Nash, Jennifer DeSanto, Carol McKinley, Timothy R Morgan, John C Hoefs, John R Craig, M Mazen Jamal, Muhammad Sheikh, Choon Park, William M Lee, Thomas E Rogers, Peter F Malet, Janel Shelton, Nicole Crowder, Rivka Elbein, Nancy Liston, Sugantha Govindarajan, Carol B Jones, Susan L Milstein, Anna S Lok, Robert J Fontana, Joel K Greenson, Pamela A Richtmyer, R Tess Bonham, Mitchell L Shiffman, Richard K Sterling, Melissa J Contos, A Scott Mills, Charlotte Hofmann, Paula Smith, Marc G Ghany, T Jake Liang, David Kleiner, Yoon Park, Elenita Rivera, Vanessa Haynes-Williams, Leonard B Seeff, Patricia R Robuck, Jay H Hoofnagle, Chihiro Morishima, David R Gretch, Minjun Chung Apodaca, Rohit Shankar, Natalia Antonov, Kristin K Snow, Anne M Stoddard, Zachary D Goodman, Fanny Monge, Michelle Parks, Gary L Davis, Guadalupe Garcia-Tsao, Michael Kutner, Stanley M Lemon, Robert P Perrillo, Gyongyi Szabo, Barbara F Banner, Neal D Freedman, Teresa M Curto, Karen L Lindsay, Elizabeth C Wright, Rashmi Sinha, James E Everhart, HALT-C TRIAL GROUP, Maureen Cormier, Donna Giansiracusa, Herbert L Bonkovsky, Gloria Borders, Michelle Kelley, Adrian M Di Bisceglie, Bruce Bacon, Brent Neuschwander-Tetri, Elizabeth M Brunt, Debra King, Harvard Clinical, Jules L Dienstag, Raymond T Chung, Andrea E Reid, Atul K Bhan, Wallis A Molchen, David P Lundmark, Gregory T Everson, Thomas Trouillot, Marcelo Kugelmas, S Russell Nash, Jennifer DeSanto, Carol McKinley, Timothy R Morgan, John C Hoefs, John R Craig, M Mazen Jamal, Muhammad Sheikh, Choon Park, William M Lee, Thomas E Rogers, Peter F Malet, Janel Shelton, Nicole Crowder, Rivka Elbein, Nancy Liston, Sugantha Govindarajan, Carol B Jones, Susan L Milstein, Anna S Lok, Robert J Fontana, Joel K Greenson, Pamela A Richtmyer, R Tess Bonham, Mitchell L Shiffman, Richard K Sterling, Melissa J Contos, A Scott Mills, Charlotte Hofmann, Paula Smith, Marc G Ghany, T Jake Liang, David Kleiner, Yoon Park, Elenita Rivera, Vanessa Haynes-Williams, Leonard B Seeff, Patricia R Robuck, Jay H Hoofnagle, Chihiro Morishima, David R Gretch, Minjun Chung Apodaca, Rohit Shankar, Natalia Antonov, Kristin K Snow, Anne M Stoddard, Zachary D Goodman, Fanny Monge, Michelle Parks, Gary L Davis, Guadalupe Garcia-Tsao, Michael Kutner, Stanley M Lemon, Robert P Perrillo, Gyongyi Szabo, Barbara F Banner
Abstract
Background & aims: High-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated.
Methods: Patients (n=885) from the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with peginterferon α-2a (180 μg/wk) and ribavirin (1000-1200 mg/day). We assessed patients for early virologic response (2 log10 reduction in level of hepatitis C virus RNA at week 12; n=466), and undetectable hepatitis C virus RNA at weeks 20 (n=320), 48 (end of treatment, n=284), and 72 (sustained virologic response; n=157).
Results: Median log10 drop from baseline to week 20 was 2.0 (interquartile range [IQR], 0.6-3.9) among nondrinkers and 4.0 (IQR, 2.1-4.7) among patients that drank 3 or more cups/day of coffee (P trend<.0001). After adjustment for age, race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1-3.6; P trend=.004) for early virologic response, 2.1 (95% CI: 1.1-3.9; P trend=.005) for week 20 virologic response, 2.4 (95% CI: 1.3-4.6; P trend=.001) for end of treatment, and 1.8 (95% CI: 0.8-3.9; P trend=.034) for sustained virologic response.
Conclusions: High-level consumption of coffee (more than 3 cups per day) is an independent predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis C.
Trial registration: ClinicalTrials.gov NCT00006164.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
Figures
Source: PubMed